全文获取类型
收费全文 | 32606篇 |
免费 | 2154篇 |
国内免费 | 222篇 |
专业分类
耳鼻咽喉 | 491篇 |
儿科学 | 786篇 |
妇产科学 | 371篇 |
基础医学 | 4061篇 |
口腔科学 | 478篇 |
临床医学 | 3443篇 |
内科学 | 7661篇 |
皮肤病学 | 246篇 |
神经病学 | 3254篇 |
特种医学 | 1368篇 |
外科学 | 5354篇 |
综合类 | 324篇 |
一般理论 | 72篇 |
预防医学 | 2223篇 |
眼科学 | 431篇 |
药学 | 2086篇 |
中国医学 | 25篇 |
肿瘤学 | 2308篇 |
出版年
2023年 | 150篇 |
2022年 | 233篇 |
2021年 | 746篇 |
2020年 | 415篇 |
2019年 | 729篇 |
2018年 | 868篇 |
2017年 | 595篇 |
2016年 | 689篇 |
2015年 | 795篇 |
2014年 | 1148篇 |
2013年 | 1456篇 |
2012年 | 2365篇 |
2011年 | 2424篇 |
2010年 | 1398篇 |
2009年 | 1161篇 |
2008年 | 2182篇 |
2007年 | 2367篇 |
2006年 | 2178篇 |
2005年 | 2194篇 |
2004年 | 1953篇 |
2003年 | 1866篇 |
2002年 | 1824篇 |
2001年 | 392篇 |
2000年 | 311篇 |
1999年 | 349篇 |
1998年 | 377篇 |
1997年 | 316篇 |
1996年 | 263篇 |
1995年 | 253篇 |
1994年 | 219篇 |
1993年 | 204篇 |
1992年 | 195篇 |
1991年 | 209篇 |
1990年 | 174篇 |
1989年 | 153篇 |
1988年 | 128篇 |
1987年 | 128篇 |
1986年 | 119篇 |
1985年 | 127篇 |
1984年 | 157篇 |
1983年 | 124篇 |
1982年 | 138篇 |
1981年 | 125篇 |
1980年 | 98篇 |
1979年 | 68篇 |
1978年 | 73篇 |
1977年 | 61篇 |
1976年 | 44篇 |
1974年 | 42篇 |
1971年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
991.
992.
993.
994.
995.
Aminoglycosides for patients undergoing intermittent hemodialysis (IHD) have traditionally been dosed at half the normal dose administered at the end of a hemodialysis session. Several investigations have suggested that administering higher doses preceding or with the initiation of dialysis would more readily optimize pharmacodynamic parameters. However, the selection of an optimal aminoglycoside dosing strategy in patients receiving IHD is complex and requires consideration of numerous factors, precluding a singular approach. By reviewing aminoglycoside pharmacokinetics, pharmacodynamics, risks for toxicity and resistance development, and practical considerations, we derive indication‐ and setting‐ specific recommendations. We identify some areas (definitive therapy of gram‐negative infections in patients receiving predictable hemodialysis sessions, for example) where dosing preceding or with the initiation of dialysis is optimal and feasible, and others (gram‐positive synergy, unstable patients with poor/unpredictable vascular access) where postdialysis dosing remains preferred. Finally, given the dearth of data exploring the pharmacodynamics and clinical outcomes of IHD patients receiving aminoglycoside therapy, we identify several key questions in need of investigation. 相似文献
996.
Gianlorenzo?Dionigi Hoon?Yub?KimEmail author Gregory?W.?Randolph Che-Wei?Wu Hui?Sun Xiaoli?Liu Marcin?Barczynski Feng-Yu?Chiang 《Surgery today》2016,46(7):785-791
Purposes
Cernea classification is applied to describe the external branch of the superior laryngeal nerve (EBSLN). Using intraoperative neural monitoring we evaluated whether or not this classification is useful for predicting which EBSLN subtype has an increased risk of injury.Methods
An analysis of 400 EBSLN. The identification of EBSLN was achieved with both cricothyroid muscle twitch and the glottis evoked electromyography response. We defined S1 initial EBSLN stimulation at identification and S2 final nerve stimulation achieved in the most cranial aspect of the nerve exposed above the area of surgical dissection after superior artery ligation.Results
The mean S1 amplitude acquired was 259+/67 (180–421), 321 +/79 (192–391), 371 +/38 (200–551) μV, respectively, for type 1, 2A, 2B (p = 0.08). The S1 and S2 amplitudes were similar in type 1 (p = 0.3). The S1 and S2 determinations changed significantly in type 2A and 2B (p = 0.04 and 0.03). EBSLN which demonstrated a >25 % decreased amplitude in S2 increased significantly from Type 1 (4.9 %) to Type 2A (11.2 %) and 2B (18 %) (p = 0.01). None of type 1, 2.8 % type 2A and 3 % type 2B showed a loss of EBSLN conductivity. The latency determinations did not vary significantly for any parameter compared.Conclusions
The Cernea classification was, therefore, found to predict the risk of EBSLN stress. We identified amplitude differences between S1 and S2 determinations in type 2A and 2B, thus confirming that surgical dissection in these subtypes is, therefore, extremely difficult to perform.997.
Tobacco Use Among Siblings of Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study
下载免费PDF全文
![点击此处可从《Pediatric blood & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
David Buchbinder MD MSHS Kevin Oeffinger MD Conrado Franco‐Villalobos BS MS Yutaka Yasui PhD Melissa A. Alderfer PhD Gregory T. Armstrong MD Jacqueline Casillas MD MSHS Jennifer Ford MD Kevin R. Krull PhD Wendy Leisenring PhD Christopher Recklitis PhD MPH Leslie L. Robison PhD Lonnie K. Zeltzer MD E. Anne Lown DrPH 《Pediatric blood & cancer》2016,63(2):326-333
998.
999.
Joseph J. Pariser Vignesh T. Packiam Melanie A. Adamsky Gregory T. Bales 《Current urology reports》2016,17(8):57
The definitive treatment for symptomatic large volume (>80 mL) benign prostatic hyperplasia (BPH) is simple prostatectomy (SP). This can be performed by utilizing a retropubic, suprapubic, or a combined approach. The latter two approaches allow for the management of concomitant bladder diverticulum or stones through the same incision. Each approach affords unique technical strengths and weaknesses that must be considered in light of patient characteristics and concomitant pathology. SP allows for removal of the entire prostatic adenoma while obviating some of the neurovascular and continence issues that can arise from radical prostatectomy. Concerns with SP include its relatively high perioperative morbidity, notably bleeding. Therefore, there is increasing interest in less invasive options, including enucleation procedures and minimally invasive SP. This review presents an update regarding trends and outcomes of SP, as well as the effectiveness and popularity of alternative treatments. 相似文献
1000.
Emma Gannan MBBS Jeremy Khoo MBBS Sophie Nightingale MBBS FRACS Thomas Surya Suhardja MBBS Jocelyn Lippey MBBS FRACS Holly Keane MBBS FRACS Kian Jin Tan MBBS David Clouston MBBS FRACPA Alexandra Gorelik PhD Gregory Bruce Mann MBBS PhD FRACS The Melbourne Breast Group 《The breast journal》2016,22(4):413-419
To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1‐2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009–2010 to 2011–2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009–2010 and 22.2% in 2011–2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011‐eligible and ‐ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease. 相似文献